Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis Rein Therapeutics (NASDAQ:RNTX) has dosed the first patient in a randomized, double-blind, placebo-controlled Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis (IPF) after the FDA cleared the company to resume the program.The trial will enroll ~120 patients across placebo, low and high dose groups in five countries, expects enrollment through mid-2027, and anticipates interim data in H2 2026. Initial activity is at five U.S. sites with planned expansion up to 50 sites.

#RNTX Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis

www.stocktitan.net/news/RNTX/rein-therapeut...

Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis Rein Therapeutics (NASDAQ:RNTX) announced that the European Commission granted orphan drug designation to its lead candidate LTI-03 for idiopathic pulmonary fibrosis (IPF) on Jan 20, 2026.The decision follows a positive COMP opinion and was supported by preclinical data showing improved survival and lung function. The EU designation (No. EU/3/25/3188) recognizes the seriousness of IPF and may provide regulatory incentives including reduced development fees, potential market exclusivity after approval, and streamlined regulatory interactions to aid clinical development.

#RNTX Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis

www.stocktitan.net/news/RNTX/rein-therapeut...

Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF Rein Therapeutics (NASDAQ: RNTX) reported a new medRxiv preprint (Nov 6, 2025) describing an inhaled, randomized dose‑escalation study of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients.The authors reported that LTI-03 was generally well tolerated, showed reductions in multiple fibrosis‑associated biomarkers, and appeared to preserve alveolar epithelial type II (AT2) progenitor cells, which are important for lung repair. Investigators said the data indicate lung target engagement and support continued development in the ongoing global Phase 2 RENEW trial.

#RNTX Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF

www.stocktitan.net/news/RNTX/rein-therapeut...

Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis Rein Therapeutics (NASDAQ: RNTX) announced that the U.S. Food and Drug Administration has lifted the full clinical hold on its Phase 2 RENEW trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) after reviewing Rein’s complete response submission.The company expects to resume U.S. enrollment in late 2025 or early 2026 across ~20 U.S. sites, complementing ~30 global sites. The study will enroll up to 120 patients, assess safety, tolerability and efficacy with key secondaries including FVC and imaging measures, and plans initial topline data in Q3 2026. Rein stated early data suggest LTI-03 may slow fibrosis and support lung repair.

#RNTX Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

www.stocktitan.net/news/RNTX/rein-therapeut...

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis Rein Therapeutics (NASDAQ: RNTX) announced EMA authorization on Oct 9, 2025 to start its global Phase 2 RENEW trial of LTI-03 for idiopathic pulmonary fibrosis (IPF).The EMA approval covers study sites in Germany and Poland; the company previously received clearance from the U.K. MHRA. LTI-03 is described as a first-in-class therapy intended to both reduce lung scarring and promote tissue repair. The approvals position Rein to begin multi-region patient enrollment and advance its lead candidate through Phase 2.

#RNTX Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

www.stocktitan.net/news/RNTX/rein-therapeut...

Novel IPF Treatment Advances: Rein Therapeutics' LTI-03 Targets Both Fibrosis and Lung Regeneration in Phase 2 Biotech firm Rein Therapeutics to launch RENEW trial for LTI-03 in idiopathic pulmonary fibrosis, enrolling 120 patients over 24 weeks. Initial data expected 2026.

#RNTX Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

www.stocktitan.net/news/RNTX/rein-therapeut...

XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration XtalPi (2228.HK) and DoveTree Medicines have announced a groundbreaking $6 billion strategic collaboration in AI-driven drug discovery. The partnership combines XtalPi's AI and robotics platform with DoveTree's biological expertise to develop novel therapeutics across multiple disease areas.Under the agreement, DoveTree receives exclusive global rights and will pay XtalPi an upfront payment of $51 million, with $49 million in near-term payments and up to $5.89 billion in milestone payments and tiered royalties. The collaboration will focus on developing first-in-class candidates in oncology, immunology, inflammation, neurology, and metabolic diseases.DoveTree, founded by renowned drug developer Dr. Gregory Verdine, brings expertise in "drugging the undruggable" targets, while XtalPi contributes its intelligent de novo drug discovery platform spanning multiple modalities including small molecules, biologics, ADCs, and molecular glues.

#ENTA #RNTX #WVE XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration

www.stocktitan.net/news/ENTA/xtal-pi-and-do...

Rein Therapeutics Lands $21M Strategic Financing to Advance Breakthrough IPF Drug Trial Strategic $21M financing deal enables Rein's Phase 2 IPF trial advancement. Includes $6M pre-paid advance and $15M equity purchase agreement. Learn full details.

#RNTX Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing

www.stocktitan.net/news/RNTX/rein-therapeut...

Rein Therapeutics Postpones Annual Shareholder Meeting Due to Lack of Quorum Rein Therapeutics announced the adjournment of its annual stockholders' meeting to July 23, 2025, due to insufficient attendance. Stakeholders encouraged to vote.

Rein Therapeutics Postpones Annual Shareholder Meeting Due to Lack of Quorum #Rein_Therapeutics #LTI-03 #RNTX

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders Rein Therapeutics (NASDAQ: RNTX), a biopharmaceutical company focused on developing first-in-class medications for orphan pulmonary and fibrosis conditions, has announced the adjournment of its 2025 Annual Meeting of Stockholders due to lack of quorum. The meeting will reconvene on July 23, 2025, at 9:00 a.m. Eastern Time.The record date remains May 5, 2025, and stockholders can continue voting until 11:59 p.m. Eastern Time on July 22, 2025. The board strongly recommends voting "FOR" all proposals outlined in the proxy statement filed with the SEC on May 12, 2025. Previously submitted proxies will remain valid unless properly revoked.

#RNTX Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

www.stocktitan.net/news/RNTX/rein-therapeut...

Breakthrough IPF Drug Enters Phase 2 Trial: Rein's Novel Treatment Could Transform Pulmonary Fibrosis Care Novel multi-pathway IPF treatment begins Phase 2 trial across 50 global sites. 120-patient study evaluating breakthrough Caveolin-1 therapy. See interim data timeline.

#RNTX #IQV Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

www.stocktitan.net/news/RNTX/rein-therapeut...

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference Rein Therapeutics (NASDAQ: RNTX) presented two posters at the American Thoracic Society 2025 International Conference supporting their lead asset LTI-03 for treating idiopathic pulmonary fibrosis (IPF). The first poster demonstrated LTI-03's ability to reduce profibrotic proteins and increase solRAGE production without causing cellular necrosis, unlike current treatment nintedanib. The second poster showed LTI-03's potential to sustain type 2 alveolar epithelial cell (AEC2) viability and support AEC2 to AEC1 differentiation. The company's Phase 2 RENEW trial is currently ongoing, with topline interim data expected in the first half of 2026. Additionally, their second-generation peptide LTI-2355 showed promising results in preclinical studies, demonstrating protective effects on normal lung alveolospheres.

#RNTX Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

www.stocktitan.net/news/RNTX/rein-therapeut...

BREAKING NEWS: ( NASDAQ: #RNTX ) Expected earnings - Rein Therapeutics Inc.

Rein Therapeutics' Latest Financial Results and Future Prospects in Biopharmaceuticals Rein Therapeutics reports its first quarter 2025 financial results, updates on RENEW trial, and collaborations, signaling a dynamic future.

Rein Therapeutics' Latest Financial Results and Future Prospects in Biopharmaceuticals #USA #Austin #Rein_Therapeutics #LTI-03 #RNTX

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Rein Therapeutics (NASDAQ: RNTX) reported Q1 2025 financial results and provided key business updates. The company has initiated the RENEW Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis (IPF), with topline interim data expected in H1 2026. The trial will enroll 120 patients to evaluate two dosage levels. Rein secured two patents for LTI-03's formulation and partnered with Qureight for AI-powered image analysis. Financial highlights include: cash position of $7.4M as of March 31, 2025, Q1 net loss of $5.5M ($0.25 per share), and runway extended through September 2025 following $5.28M raised in April transactions. R&D expenses decreased to $3.1M from $3.5M YoY, while G&A expenses reduced to $2.5M from $3.7M.

#RNTX Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/RNTX/rein-therapeut...

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF Rein Therapeutics (NASDAQ: RNTX) has initiated the RENEW Phase 2 trial for its lead drug candidate LTI-03 in idiopathic pulmonary fibrosis (IPF) patients. The trial will enroll approximately 120 patients across 50 global sites, with topline data expected in H1 2026.The study is designed as a multi-center, randomized, double-blind, placebo-controlled trial testing two dose levels: a low dose cohort (2.5mg BID) and a high dose cohort (5mg BID). The primary endpoint focuses on treatment-emergent adverse events through Week 24, while secondary endpoints include FVC and HRCT measurements.In the previous Phase 1b trial, LTI-03 demonstrated promising results with positive trends in 7 out of 8 biomarkers in Cohort 2, with 5 showing dose dependence and 4 achieving statistical significance in the combined cohort data.

#RNTX Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

www.stocktitan.net/news/RNTX/rein-therapeut...

Rein Therapeutics to Showcase Innovative Therapies at Life Sciences Conference 2025 Rein Therapeutics is set to present its groundbreaking therapies at the Citizens Life Sciences Conference 2025, aimed at addressing critical medical needs.

Rein Therapeutics to Showcase Innovative Therapies at Life Sciences Conference 2025 #USA #New_York #biopharmaceuticals #Rein_Therapeutics #RNTX

Game-Changing Patents: How Rein Therapeutics' New Inhaled Drug Could Transform Lung Disease Treatment Novel dry powder therapy targets multiple respiratory diseases with dual-action mechanism. Phase 2 trials for pulmonary fibrosis starting soon. Get exclusive details.

#RNTX Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

www.stocktitan.net/news/RNTX/rein-therapeut...

Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Rein Therapeutics (NASDAQ: RNTX) has reported its Q4 and full-year 2024 financial results, highlighting progress in its lead asset LTI-03 for idiopathic pulmonary fibrosis (IPF). The company announced positive topline results from Phase 1b Cohort 2 trial, with four biomarkers achieving statistical significance and five showing dose-dependent effects.Financial highlights include: Cash position of $12.9M as of December 31, 2024 (down from $17.3M in 2023)Q4 2024 net loss of $41.0M, including $37.0M non-cash impairment chargeFull-year R&D expenses increased to $14.2M from $4.0M in 2023G&A expenses rose to $13.9M from $11.4M in 2023The company plans to initiate a Phase 2 trial for LTI-03 in IPF during first half of 2025, subject to funding. Additionally, Rein entered an exclusive option agreement with Advancium Health Network for ALRN-6924 and completed its rebranding from Aileron Therapeutics in January 2025.

#RNTX Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/RNTX/rein-therapeut...

Aileron Rebrands as Rein Therapeutics Following Breakthrough IPF Drug Trial Success Aileron transforms into Rein Therapeutics (RNTX), backed by positive Phase 1b results for IPF treatment LTI-03. Company advances two clinical-stage assets with orphan drug status.

#ALRN #RNTX Aileron Therapeutics Announces Rebranding to Rein Therapeutics

www.stocktitan.net/news/ALRN/aileron-therap...